Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | -99.76% |
04-02 | Motion for Asset Sale Approved for Biocept, Inc. | CI |
2023 | Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index | CI |
Sales 2021 | 61.25M 4.9B | Sales 2022 | 25.86M 2.07B | Capitalization | 9.04M 724M |
---|---|---|---|---|---|
Net income 2021 | -2M -160M | Net income 2022 | -32M -2.56B | EV / Sales 2021 | 0.73 x |
Net cash position 2021 | 16.19M 1.3B | Net cash position 2022 | 788K 63.08M | EV / Sales 2022 | 0.32 x |
P/E ratio 2021 |
-18.9
x | P/E ratio 2022 |
-0.28
x | Employees | 50 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
Latest transcript on Biocept, Inc.
6 months | -99.97% | ||
Current year | -99.76% |
Managers | Title | Age | Since |
---|---|---|---|
Barbara Blouw
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/19 |
Nathaniel Sweed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | 60 | 07/03/22 |
Date | Price | Change | Volume |
---|---|---|---|
23/04/24 | 0.0001 | 0.00% | 2,710 |
19/04/24 | 0.0001 | 0.00% | 5,074 |
Delayed Quote OTC Markets, April 23, 2024 at 08:02 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-99.76% | 262 | |
+0.89% | 12.8B | |
-10.29% | 7.61B | |
+1.78% | 5.41B | |
-1.16% | 4.51B | |
+5.74% | 4.49B | |
-50.70% | 3.29B | |
+12.21% | 2.73B | |
-16.13% | 2.02B | |
-11.50% | 1.73B |
- Stock Market
- Equities
- BIOCQ Stock